A new study found that a third dosage of Sinovac's Covid-19 vaccine does not give enough protection against the Omicron strain, despite the vaccine maker's claims.
According to Nikkei Asia, the study was conducted by the University of Hong Kong (HKU) and the Chinese University of Hong Kong, which revealed that a third dose of the Covid-19 vaccine, which is one of the world's most extensively used, did not develop enough virus-neutralizing antibodies.
The third dosage of Sinovac, also known as CoronaVac, a vaccine developed by Pfizer and BioNTech, however, considerably increased protection for people who had previously received two doses of Sinovac, according to the research. According to Malik Peiris, the HKU researcher who lead the research, a Pfizer booster will "achieve optimum protection against (the) Omicron variant."
Sinovac stated last week that a third treatment was "effective in enhancing serum neutralising against the omicron strain" in its own trial. According to the study, 94% of those who got three Sinovac doses produced adequate neutralising antibodies. The company did not specify what type of antibody levels were created by three doses.
COVID-19 won't be the last pandemic humanity will face, warns UN chief
Israeli PM Bennett quarantines after daughter tests Covid positive
Election commissions in Afghanistan dissolves by Taliban-run government